Predictive biomarkers of recurrence may not be useful for deescalating treatment of breast ductal carcinoma in situ due to de novo ipsilateral breast carcinoma development (#148)
Tanjina Kader
1
,
Sakshi Mahale
1
,
Magnus Zethoven
1
,
Hugo Saunders
1
,
Dorothea Lesche
1
,
David Byrne
1
,
Maree Pechlevanis
1
,
Olivia Craig
1
,
Lauren Tjouka
1
,
Jia-Min Pang
1
,
Lisa Devereux
1
,
Eloise House
2
,
Shona Hendry
2
,
Sureshni Jayasinghe
2
,
Michael Toss
3
,
Islam Miligy
3
,
Emad Rakha
3
,
Stephen Fox
1
,
Bruce Mann
4
,
Ian Campbell
1
,
Kylie Gorringe
1
- Peter MacCallum Cancer Centre, Parkville, VIC, Australia
- Anatomical Pathology, St Vincent's Hospital, Melbourne, VIC, Australia
- Histopathology, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital, Nottingham, United Kingdom
- The Breast Service, The Royal Women's Hospital, Melbourne, VIC, Australia